DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE : revenue, balance sheet and financial ratios

DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE is a French company founded 26 years ago, specialized in the sector Intermédiaires spécialisés dans le commerce d'autres produits spécifiques. Based in MATOURY (97351), this company of category PME shows in 2025 a revenue of 952 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE (SIREN 424480176)
Indicator 2025 2015
Revenue 952 084 € 673 290 €
Net income 46 807 € -14 565 €
EBITDA 80 218 € -10 033 €
Net margin 4.9% -2.2%

Revenue and income statement

Im Jahr 2025 erzielt DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE einen Umsatz von 952 k€. Vs 2015, Wachstum von +41% (673 k€ -> 952 k€). Nach Abzug des Verbrauchs (658 k€) beträgt die Bruttomarge 294 k€, d.h. eine Rate von 31%. Dieses Verhältnis misst die Fähigkeit, aus der Geschäftstätigkeit Wert zu schaffen. EBITDA (= Bruttomarge - Personalkosten - Steuern) erreicht 80 k€, was 8.4% des Umsatzes entspricht. Positiver Schereneffekt: EBITDA-Marge verbessert sich um +9.9 Punkte. Dieses Niveau der operativen Marge ist für die Branche zufriedenstellend. Das Nettoergebnis beträgt 47 k€, d.h. 4.9% des Umsatzes.

Revenue (2025) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

952 084 €

Gross margin (2025) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

293 600 €

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

80 218 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

74 880 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

46 807 €

EBITDA margin (2025) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

8.4%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

Die Verschuldungsquote (= Finanzschulden / Eigenkapital x 100) beträgt 8%. Dieses niedrige Niveau spiegelt eine solide Finanzstruktur wider. Die finanzielle Autonomie (= Eigenkapital / Bilanzsumme x 100) erreicht 35%. Das Gleichgewicht zwischen Eigenkapital und Schulden ist zufriedenstellend. Die Schuldenrückzahlungskapazität zeigt, dass es 0.3 Jahre Cashflow braucht. Diese kurze Periode zeigt eine ausgezeichnete Schuldentragfähigkeit. Der Cashflow beträgt 4.9% des Umsatzes.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

8.36%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

34.674%

Cash flow / Revenue (2025) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

4.916%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.304

Solvency indicators evolution
DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE

Sector positioning

Verschuldungsgrad
8.36 2025
2015
2025
Q1: 0.03
Med: 6.12
Q3: 38.62
Average +44 pts over 2 years

Im Jahr 2025 liegt über dem Median der Branche das verschuldungsgrad von DISTRIBUTION ET REPRESENT... (8.36). Dieses Verhältnis misst das Gewicht der Schulden im Verhältnis zum Eigenkapital. Eine Reduzierung könnte die finanzielle Stärke verbessern.

Finanzielle Autonomie
34.67% 2025
2015
2025
Q1: 21.35%
Med: 44.38%
Q3: 70.12%
Average +14 pts over 2 years

Im Jahr 2025 liegt unter dem Median der Branche das finanzielle autonomie von DISTRIBUTION ET REPRESENT... (34.7%). Dieses Verhältnis stellt den Anteil des Eigenkapitals an der Gesamtfinanzierung dar. Eine Verbesserung würde die Wettbewerbsposition stärken.

Rückzahlungsfähigkeit
0.3 ans 2025
2015
2025
Q1: 0.0 ans
Med: 0.0 ans
Q3: 0.67 ans
Average +38 pts over 2 years

Im Jahr 2025 liegt über dem Median der Branche das rückzahlungsfähigkeit von DISTRIBUTION ET REPRESENT... (0.3 an). Dieses Verhältnis gibt die Anzahl der Jahre an, die zur Rückzahlung der Schulden mit dem Cashflow benötigt werden. Eine Reduzierung könnte die finanzielle Stärke verbessern.

Liquidity ratios

Die Liquiditätsquote beträgt 149.29. Das Unternehmen verfügt über 2€ liquide Mittel für jeden 1€ kurzfristiger Schulden.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

149.295

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.0

Liquidity indicators evolution
DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE

Sector positioning

Liquiditätsquote
149.29 2025
2015
2025
Q1: 144.58
Med: 224.91
Q3: 433.28
Average

Im Jahr 2025 liegt unter dem Median der Branche das liquiditätsquote von DISTRIBUTION ET REPRESENT... (149.29). Dieses Verhältnis misst die Fähigkeit, kurzfristige Schulden mit Umlaufvermögen zu decken. Eine Verbesserung würde die Wettbewerbsposition stärken.

Zinsdeckung
0.0x 2025
2015
2025
Q1: 0.0x
Med: 0.0x
Q3: 0.66x
Average

Im Jahr 2025 liegt unter dem Median der Branche das zinsdeckung von DISTRIBUTION ET REPRESENT... (0.0x). Dieses Verhältnis gibt an, wie oft das Betriebsergebnis die Zinsaufwendungen deckt. Eine Verbesserung würde die Wettbewerbsposition stärken.

Working capital requirement (WCR) and payment terms

Der Betriebskapitalbedarf (WCR) misst die zeitliche Lücke. Durchschnittliche Kundenzahlungsfrist: 108 Tage. Lieferantenfrist: 136 Tage. Günstige Situation. Die Bestandsumschlagsdauer beträgt 1 Tage. Schneller Umschlag, Zeichen guter Bestandsführung. Der WCR repräsentiert 154 Tage Umsatz.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

408 216 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

108 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

136 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

1 j

WCR in days of revenue (2025) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

154 j

WCR and payment terms evolution
DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE

Positioning of DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE in its sector

Comparison with sector Intermédiaires spécialisés dans le commerce d'autres produits spécifiques

Valuation estimate

Based on 50 transactions of similar company sales (all years), the value of DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE is estimated at 178 978 € (range 93 825€ - 472 868€). With an EBITDA of 80 218€, the sector multiple of 1.8x is applied. The price/revenue ratio is 0.32x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2025
50 tx
93k€ 178k€ 472k€
178 978 € Range: 93 825€ - 472 868€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
80 218 € × 1.8x
Estimation 145 834 €
75 984€ - 495 440€
Revenue Multiple 30%
952 084 € × 0.32x
Estimation 303 475 €
151 204€ - 578 660€
Net Income Multiple 20%
46 807 € × 1.6x
Estimation 75 094 €
52 361€ - 257 753€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 50 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Intermédiaires spécialisés dans le commerce d'autres produits spécifiques)

Compare DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE with other companies in the same sector:

Voir toutes les statistiques du secteur Intermédiaires spécialisés dans le commerce d'autres produits spécifiques

Frequently asked questions about DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE

What is the revenue of DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE ?

The revenue of DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE in 2025 is 952 k€.

Is DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE profitable?

Yes, DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE generated a net profit of 47 k€ in 2025.

Where is the headquarters of DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE ?

The headquarters of DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE is located in MATOURY (97351), in the department Guyane.

Where to find the tax return of DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE ?

The tax return of DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE operate?

DISTRIBUTION ET REPRESENTATION PHARMACEUTIQUE ANTILLES-GUYANE operates in the sector Intermédiaires spécialisés dans le commerce d'autres produits spécifiques (NAF code 46.18Z). See the 'Sector positioning' section above to compare the company with its competitors.